
|Articles|October 17, 2012
FDA approves treatment for cystinosis
The FDA has approved cysteamine ophthalmic solution (Cystaran, Sigma-Tau Pharmaceuticals) 0.44% for corneal cystine crystal accumulation in patients with cystinosis.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Harrow completes acquisiton of Melt Pharmaceuticals
2
Coave Therapeutics reveals lead gene therapy program, CoTx-10
3
Foundation Fighting Blindness releases 4-year RUSH2A data to public
4
Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1
5


















































.png)


